Propanc Biopharma, Inc.
PPCB
Positions held
Your positionsPPCB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $4.63M | Enterprise value | $2.66M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.04 | Beta | 3.33 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.6% | ROA | -70.1% | Debt / equity | 0.05 |
| Current ratio | 2.55 | Free cash flow | $1.66M | Analyst recommendation | none | Mean target | — |
| 52w high | $48.75 | 52w low | $0.46 |
Quarterly
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$6.4M | -$3.1M | -$4.8M | -$4.1M | -$54.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$6.4M | -$3.7M | -$4.7M | -$3.6M | -$53.1M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$58.9M | -$1.8M | -$2.7M | -$2.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$57.3M | -$1.5M | -$1.8M | -$2.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
2026-09-22 · Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
2026-09-09 · Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
2026-08-27 · BC-Most Active Stocks
2026-08-27 · Propanc Biopharma Reports PRP Preclinical Pancreatic Cancer Data Showing Over 90% Tumor Growth Inhibition
2026-08-18 · Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
2026-08-05 · Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
Price (daily)
Full chart · RSI · MACD · patterns